Literature DB >> 21340746

The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer.

Yogesh Kumar Vashist1, Asad Kutup, Safije Musici, Emre F Yekebas, Sormeh Mina, Guentac Uzunoglu, Oliver Zehler, Alexandra Koenig, Guelle Cataldegirmen, Maximillian Bockhorn, Katharina Effenberger, Viacheslav Kalinin, Klaus Pantel, Jakob R Izbicki.   

Abstract

BACKGROUND: Genetic variations in cancer patients may serve as important prognostic indicators of clinical outcome. The GNAS1 T393C single nucleotide polymorphism (SNP) diversely correlates with the clinical outcome in cancer. The aim of this study was to evaluate the potential prognostic value of T393C-SNP in complete resected only surgically treated esophageal cancer (EC).
METHODS: Genomic DNA was extracted from peripheral blood leucocytes of 190 patients who underwent only complete surgical resection for EC. T393C-SNP was correlated with clinic-pathological parameters, tumor cell dissemination in bone marrow (DTC) and clinical outcome.
RESULTS: T-allele carriers had more advanced disease due to presence of lymph node metastasis (P < 0.0001) and DTC (P = 0.01) and higher recurrence rate (P = 0.01) compared to CC genotype. The disease-free (P < 0.001) and overall survival (P < 0.001) was better in CC compared to TT and TC patients. In the multivariate Cox regression disease-stage adjusted analysis the T393C-SNP was identified as a strong independent prognostic factor for recurrence (hazard ratio 1.8, P = 0.01) and survival (hazard ratio 2.5, P < 0.001) in EC patients.
CONCLUSION: Determination of T393C-SNP preoperatively will allow allocation of EC patients into different risk profiles which may help to stratify patients eligible for neoadjuvant and or adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21340746     DOI: 10.1007/s13402-011-0016-x

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  43 in total

Review 1.  Adjuvant and neoadjuvant therapy for esophageal cancer: a critical reappraisal.

Authors:  Brendan C Visser; Alan P Venook; Marco G Patti
Journal:  Surg Oncol       Date:  2003-07       Impact factor: 3.279

2.  Increased expression of Gs(alpha) enhances activation of the adenylyl cyclase signal transduction cascade.

Authors:  X Yang; F Y Lee; G S Wand
Journal:  Mol Endocrinol       Date:  1997-07

3.  Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells.

Authors:  E Borgen; B Naume; J M Nesland; G Kvalheim; K Beiske; O Fodstad; I Diel; E F Solomayer; P Theocharous; R C Coombes; B M Smith; E Wunder; J P Marolleau; J Garcia; K Pantel
Journal:  Cytotherapy       Date:  1999       Impact factor: 5.414

4.  The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer.

Authors:  Ulrich H Frey; Andreas Eisenhardt; Gerd Lümmen; Herbert Rübben; Karl-Heinz Jöckel; Kurt W Schmid; Winfried Siffert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

5.  GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer.

Authors:  Ulrich H Frey; Hakan Alakus; Jeremias Wohlschlaeger; Klaus J Schmitz; Günther Winde; Hans G van Calker; Karl-Heinz Jöckel; Winfried Siffert; Kurt W Schmid
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

Review 6.  Minireview: GNAS: normal and abnormal functions.

Authors:  Lee S Weinstein; Jie Liu; Akio Sakamoto; Tao Xie; Min Chen
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

7.  GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.

Authors:  H Alakus; U Warnecke-Eberz; E Bollschweiler; S P Mönig; D Vallböhmer; J Brabender; U Drebber; S E Baldus; K Riemann; W Siffert; A H Hölscher; R Metzger
Journal:  Pharmacogenomics J       Date:  2009-03-10       Impact factor: 3.550

8.  Genetic variation in the HSD17B1 gene and risk of prostate cancer.

Authors:  Peter Kraft; Paul Pharoah; Stephen J Chanock; Demetrius Albanes; Laurence N Kolonel; Richard B Hayes; David Altshuler; Gerald Andriole; Christine Berg; Heiner Boeing; Noel P Burtt; Bas Bueno-de-Mesquita; Eugenia E Calle; Howard Cann; Federico Canzian; Yen-Ching Chen; David E Crawford; Alison M Dunning; Heather S Feigelson; Matthew L Freedman; John M Gaziano; Ed Giovannucci; Carlos Alberto Gonzalez; Christopher A Haiman; Goran Hallmans; Brian E Henderson; Joel N Hirschhorn; David J Hunter; Rudolf Kaaks; Timothy Key; Loic Le Marchand; Jing Ma; Kim Overvad; Domenico Palli; Malcolm C Pike; Elio Riboli; Carmen Rodriguez; Wendy V Setiawan; Meir J Stampfer; Daniel O Stram; Gilles Thomas; Michael J Thun; Ruth Travis; Antonia Trichopoulou; Jarmo Virtamo; Sholom Wacholder
Journal:  PLoS Genet       Date:  2005-11-25       Impact factor: 5.917

Review 9.  Host genetics and tumour metastasis.

Authors:  K W Hunter
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

10.  Genome-wide association study identifies novel breast cancer susceptibility loci.

Authors:  Douglas F Easton; Karen A Pooley; Alison M Dunning; Paul D P Pharoah; Deborah Thompson; Dennis G Ballinger; Jeffery P Struewing; Jonathan Morrison; Helen Field; Robert Luben; Nicholas Wareham; Shahana Ahmed; Catherine S Healey; Richard Bowman; Kerstin B Meyer; Christopher A Haiman; Laurence K Kolonel; Brian E Henderson; Loic Le Marchand; Paul Brennan; Suleeporn Sangrajrang; Valerie Gaborieau; Fabrice Odefrey; Chen-Yang Shen; Pei-Ei Wu; Hui-Chun Wang; Diana Eccles; D Gareth Evans; Julian Peto; Olivia Fletcher; Nichola Johnson; Sheila Seal; Michael R Stratton; Nazneen Rahman; Georgia Chenevix-Trench; Stig E Bojesen; Børge G Nordestgaard; Christen K Axelsson; Montserrat Garcia-Closas; Louise Brinton; Stephen Chanock; Jolanta Lissowska; Beata Peplonska; Heli Nevanlinna; Rainer Fagerholm; Hannaleena Eerola; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; David J Hunter; Susan E Hankinson; David G Cox; Per Hall; Sara Wedren; Jianjun Liu; Yen-Ling Low; Natalia Bogdanova; Peter Schürmann; Thilo Dörk; Rob A E M Tollenaar; Catharina E Jacobi; Peter Devilee; Jan G M Klijn; Alice J Sigurdson; Michele M Doody; Bruce H Alexander; Jinghui Zhang; Angela Cox; Ian W Brock; Gordon MacPherson; Malcolm W R Reed; Fergus J Couch; Ellen L Goode; Janet E Olson; Hanne Meijers-Heijboer; Ans van den Ouweland; André Uitterlinden; Fernando Rivadeneira; Roger L Milne; Gloria Ribas; Anna Gonzalez-Neira; Javier Benitez; John L Hopper; Margaret McCredie; Melissa Southey; Graham G Giles; Chris Schroen; Christina Justenhoven; Hiltrud Brauch; Ute Hamann; Yon-Dschun Ko; Amanda B Spurdle; Jonathan Beesley; Xiaoqing Chen; Arto Mannermaa; Veli-Matti Kosma; Vesa Kataja; Jaana Hartikainen; Nicholas E Day; David R Cox; Bruce A J Ponder
Journal:  Nature       Date:  2007-06-28       Impact factor: 49.962

View more
  2 in total

1.  TT genotype of GNAS1 T393C polymorphism predicts better outcome of advanced non-small cell lung cancer patients.

Authors:  Hong-Yun Gong; Wei-Guo Hu; Xiu-Ling Wang; Fan Zhu; Qin-Bin Song
Journal:  World J Gastrointest Oncol       Date:  2014-12-15

Review 2.  A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.

Authors:  J M Findlay; M R Middleton; I Tomlinson
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.